Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BEAM-302

Gene editing · Acts on alpha-1 antitrypsin (SERPINA1) (SERPINA1) · developed by Beam Therapeutics

Phase 1/2 Most advanced trial

BEAM Developer

1 Registered trials

What is BEAM-302?

BEAM-302 is a lipid nanoparticle (LNP)-based therapy studied for the treatment of alpha-1 antitrypsin deficiency (AATD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene editing
Targets: alpha-1 antitrypsin (SERPINA1) (SERPINA1)
Mechanism: Acts on alpha-1 antitrypsin (SERPINA1) (SERPINA1)
Therapy area: Respiratory
Developer: Beam Therapeutics Inc. (BEAM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06389877	Phase 1/2	Alpha 1-Antitrypsin Deficiency	Recruiting	BEAM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha 1-Antitrypsin Deficiency

Other drugs acting on SERPINA1

ARC-AAT Phase 2 Fazirsiran Phase 2 NTLA-3001 Phase 1/2 WVE-006 Phase 1/2

More from Beam Therapeutics

BEAM-103 Phase 1 BEAM-201 Phase 1/2 BEAM-301 Phase 1/2 Ristoglogene Autogetemcel Phase 1/2

Sources

ClinicalTrials.gov NCT06389877

Updated Oct 11, 2026. Something wrong or missing? Report it on the BEAM page.

Follow BEAM, the company behind BEAM-302

See BEAM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BEAM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z